Development and assessment of a composite score for memory in the Alzheimer's Disease Neuroimaging Initiative (ADNI)
about
Impact of the Alzheimer's Disease Neuroimaging Initiative, 2004 to 2014The impact of the Alzheimer's Disease Neuroimaging Initiative 2: What role do public-private partnerships have in pushing the boundaries of clinical and basic science research on Alzheimer's disease?The Alzheimer's prevention initiative composite cognitive test score: sample size estimates for the evaluation of preclinical Alzheimer's disease treatments in presenilin 1 E280A mutation carriersDeconstructing racial differences: the effects of quality of education and cerebrovascular risk factorsCerebrospinal fluid analysis detects cerebral amyloid-β accumulation earlier than positron emission tomographyPrediction of Alzheimer's disease pathophysiology based on cortical thickness patternsThe Bay Area Verbal Learning Test (BAVLT): Normative Data and the Effects of Repeated Testing, Simulated Malingering, and Traumatic Brain InjuryDysexecutive and amnesic AD subtypes defined by single indicator and modern psychometric approaches: relationships with SNPs in ADNI.2014 Update of the Alzheimer's Disease Neuroimaging Initiative: A review of papers published since its inception.The effectiveness and unique contribution of neuropsychological tests and the δ latent phenotype in the differential diagnosis of dementia in the uniform data set.Neuronal injury biomarkers and prognosis in ADNI subjects with normal cognition.Neuropsychiatric symptoms predict hypometabolism in preclinical Alzheimer diseaseGenetic modification of the relationship between phosphorylated tau and neurodegeneration.Longitudinal effects of metabolic syndrome on Alzheimer and vascular related brain pathology.An empirically derived composite cognitive test score with improved power to track and evaluate treatments for preclinical Alzheimer's disease.Stroke risk interacts with Alzheimer's disease biomarkers on brain aging outcomes.Frontobasal gray matter loss is associated with the TREM2 p.R47H variantBiomarker progressions explain higher variability in stage-specific cognitive decline than baseline values in Alzheimer diseaseLow levels of cerebrospinal fluid complement 3 and factor H predict faster cognitive decline in mild cognitive impairment.Alzheimer's disease risk assessment using large-scale machine learning methodsTemporal evolution of biomarkers and cognitive markers in the asymptomatic, MCI, and dementia stage of Alzheimer's diseaseCerebrospinal fluid α-synuclein and Lewy body-like symptoms in normal controls, mild cognitive impairment, and Alzheimer's diseaseAnxiety symptoms in amnestic mild cognitive impairment are associated with medial temporal atrophy and predict conversion to Alzheimer disease.The role of vascular endothelial growth factor in neurodegeneration and cognitive decline: exploring interactions with biomarkers of Alzheimer diseaseInsulin resistance predicts medial temporal hypermetabolism in mild cognitive impairment conversion to Alzheimer disease.Heterogeneity of Regional Brain Atrophy Patterns Associated with Distinct Progression Rates in Alzheimer's Disease.Memory, executive, and multidomain subtle cognitive impairment: clinical and biomarker findings.Interleukin-6: the missing element of the neurocognitive deterioration in schizophrenia? The focus on genetic underpinnings, cognitive impairment and clinical manifestation.Prognostic classification of mild cognitive impairment and Alzheimer's disease: MRI independent component analysisTrajectories of Neuropsychiatric Symptoms and Cognitive Decline in Mild Cognitive ImpairmentAdvanced psychometric analysis and the Alzheimer's Disease Neuroimaging Initiative: reports from the 2011 Friday Harbor conference.Voxel and surface-based topography of memory and executive deficits in mild cognitive impairment and Alzheimer's disease.Relationship between baseline brain metabolism measured using [¹⁸F]FDG PET and memory and executive function in prodromal and early Alzheimer's disease.Independent and Interactive Influences of the APOE Genotype and Beta-Amyloid Burden on Cognitive Function in Mild Cognitive ImpairmentParallel but not equivalent: challenges and solutions for repeated assessment of cognition over time.Genetic architecture of resilience of executive functioning.A Combined Measure of Cognition and Function for Clinical Trials: The Integrated Alzheimer's Disease Rating Scale (iADRS).Application of Latent Variable Methods to the Study of Cognitive Decline When Tests Change over Time.The executive prominent/memory prominent spectrum in Alzheimer's disease is highly heritableFive-year biomarker progression variability for Alzheimer's disease dementia prediction: Can a complex instrumental activities of daily living marker fill in the gaps?
P2860
Q26801629-684B7DB5-046E-4603-91D4-B6AD9CEC7A84Q26801634-EA3A3B85-61E9-40B4-BC85-D0626B81BAAEQ26849380-D9FBF8B4-2F3B-4D89-9401-CF5BDC281426Q27301438-4533A587-87F7-4661-A1D8-1E061C5A3553Q28273817-6D9F0C83-D614-4E3F-9029-9A904768C391Q28602247-5C055ACD-4A1A-4A80-A84D-8CC09D49D806Q30364981-3A75C3C3-373B-4F21-95A3-AED324580690Q30530793-51329524-A9AE-445A-A017-82C32B332FF3Q30971403-797816C5-FDFD-401F-879B-D47CE8A0BC47Q31140102-42ED93B3-308F-45EB-B64E-55CF3D466FFAQ33559175-87FFFFC4-E524-4FFC-A33D-7AC73A5A1F3CQ33644324-97738F5C-5606-4894-8D77-93D73FF5D0CBQ34216985-08D1B2E4-18E5-4999-BECD-DB892CF5EAF5Q34296138-AF914241-FCB8-4ACE-A13A-A3C90C287BE5Q34364368-5C17BE9C-933A-42FC-8C16-3992429F7B59Q34482685-57F96A7E-926C-4177-9BFB-D7F4B85C93CAQ34620183-07B1C706-181C-44D1-8B86-88625F045988Q34620948-B8E385D2-71E7-4552-BF6D-33EE0948F467Q34630522-76FAD4ED-F8E0-491F-9B11-04E8D2C3D2ADQ35046556-5FAB279A-2ACD-4F0C-BCA5-F02FB3CE145FQ35106997-EC80E8D6-3B69-4C0E-981F-D1160B278F03Q35151444-8F09FF2F-C433-434D-8A62-F4DF9FA7D865Q35327689-0CD3B6A3-FCF5-4CBF-8F85-91A0A6AC24CFQ35598131-6616C16F-573B-461F-A4DA-21E335F67920Q35630843-C5DB53DC-D5E4-49E9-9329-F32B88889A56Q35855414-D8842ABD-9CEA-4C77-9080-1F1E412DB62CQ35889053-4A0EC8CB-C7AC-4B9A-8EA8-B7CE97135645Q35968008-3391A303-961A-46EC-8CA9-95157249ECD0Q36100803-625CAA06-AC3F-40ED-9828-E94AD950895FQ36405533-FB8D5C92-AA0B-4D34-820C-9D3135C0FECAQ36494731-F6B1B20A-1570-4D5A-8669-AE9EC3C8191CQ36494813-E7C89F03-6A64-442D-BAB2-7D9C255700DEQ36494819-09DD3524-8365-4BEF-B039-9EC1346D8DD6Q36510006-DD1C0C84-A147-4CF2-B2D4-1EED05A145D2Q36616748-FBD3267A-FCCF-44A6-AA54-56E1B413CE18Q36713612-FD211228-CCB4-4089-AFF2-651E0E3C409BQ36725034-52D23BA7-126F-4F2A-BCC4-24AB72EA6384Q36760278-E43FEA6B-17DB-4378-987B-D80FF9BFF499Q36831778-2C4228B3-538B-4F5E-8128-1505388CC254Q36933700-CA207462-43D8-49D9-932E-02CFBF3284EB
P2860
Development and assessment of a composite score for memory in the Alzheimer's Disease Neuroimaging Initiative (ADNI)
description
2012 nî lūn-bûn
@nan
2012 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Development and assessment of ...... Neuroimaging Initiative (ADNI)
@ast
Development and assessment of ...... Neuroimaging Initiative (ADNI)
@en
type
label
Development and assessment of ...... Neuroimaging Initiative (ADNI)
@ast
Development and assessment of ...... Neuroimaging Initiative (ADNI)
@en
prefLabel
Development and assessment of ...... Neuroimaging Initiative (ADNI)
@ast
Development and assessment of ...... Neuroimaging Initiative (ADNI)
@en
P2093
P2860
P50
P921
P1476
Development and assessment of ...... Neuroimaging Initiative (ADNI)
@en
P2093
Adam Carle
Alden Gross
Dan Mungas
Danielle Harvey
Laura E Gibbons
Philip Insel
R Scott Mackin
S McKay Curtis
P2860
P2888
P304
P356
10.1007/S11682-012-9186-Z
P50
P577
2012-12-01T00:00:00Z
P6179
1031490677